The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype

Cancer Chemotherapy and Pharmacology
Kenjiro AogiShigemitsu Takashima

Abstract

Gemcitabine (GEM)-paclitaxel combination therapy has been confirmed as a standard therapy for metastatic/recurrent breast cancer (MBC) in Western countries. This study was conducted to assess the efficacy and safety of GEM-paclitaxel combination therapy in Japanese MBC patients. Patients were administered paclitaxel 175 mg/m(2) on day 1, and GEM 1,000 or 1,250 mg/m(2) on days 1 and 8 of 21-day cycle. The primary endpoint of this study was overall response rate; secondary endpoints were duration of response, time to progression, survival time and rate. Paclitaxel 175 mg/m(2) plus GEM 1,250 mg/m(2) was determined as the recommended dose. A total of 56 patients received 506 cycles of treatment (median: 7.5 cycles) with a relative dose intensity of 79.6% for GEM and 85.8% for paclitaxel. The response rate was 44.6% (25/56 patients), median time to progression 8.6 months and median survival time 27.1 months. In triple-negative patients, the response rate was 35.7% (5/14 patients), and the median time to progression was 6.0 months. The most frequent grade ≥ 3 toxicities were neutropenia (82.1%), leukopenia (62.5%) and ALT increase (14.3%). This study confirmed the efficacy and safety of GEM-paclitaxel combination therapy in Japanese ...Continue Reading

References

Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A GennariP F Conte
Apr 24, 2002·Clinical Breast Cancer·M Levine
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joyce O'ShaughnessyRobert Leonard
Dec 22, 2005·The Oncologist·Joyce O'Shaughnessy
Jan 18, 2006·International Journal of Clinical Practice·G FechnerUNKNOWN German Association Of Urologic Oncology (Auo) Bladder Cancer Study Group
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Lisa A CareyRobert C Millikan
Jul 19, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Kei Siong KhooManfred Lehnert
Mar 17, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M FriedlanderP Harnett
Aug 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy S AlbainJoyce O'Shaughnessy
Mar 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen ChanPierre Fumoleau
Apr 17, 2009·The Cochrane Database of Systematic Reviews·Sue CarrickNicholas Wilcken
May 13, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carolyn D SeibBrent T Shoji
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R GandaraPhilip C Mack
Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David J Gallagher, Nancy E Kemeny
Jul 28, 2009·Maturitas·Sumanta Kumar Pal, Joanne Mortimer

❮ Previous
Next ❯

Citations

Jul 14, 2011·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Shintaro TakaoShigemitsu Takashima
Oct 14, 2021·Journal of the American Chemical Society·Ping GaoTâp Ha-Duong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.